Arvinas Growth, Revenue, Number of Employees and Funding

Overview

Location:
New Haven, CT USA
Total Funding:$235.9M
Industry:Biotech
Founded:2013
Lead Investor(s):Nextech Invest
Press

Industry Ranking

State Ranking

Growjo 10k Ranking

Estimated Revenue & Financials

  • Arvinas's estimated revenue is currently $1.3M per year.
  • Arvinas received $55.0M in venture funding in April 2018.
  • Arvinas's estimated revenue per employee is $15765
  • Arvinas's total funding is $235.9M.

Employee Data

  • Arvinas has 85 Employees.
  • Arvinas grew their employee count by 49% last year.
  • Arvinas currently has 17 job openings.

Executive Contacts

NameTitle
Craig CrewsFounder/Chief Scientific Advisor
Andy CrewChief Technology Officer
Brad PearceAssociate Director Computational Chemistry
Elizabeth SachatelloDirector, Human Resources
Matthew BattersVice President
Keith HornbergerDirector, Chemistry
James GraceDirector
Sang Hyun LeeDirector
Mary GarfieldSenior Director Clinical Operations
Randy TeelVP Corporate Development

What Is Arvinas?

Arvinas is a pharmaceutical company focused on developing new small molecules - known as PROTACs (PROteolysis TArgeting Chimeras) - aimed at degrading disease-causing cellular proteins via proteolysis. Based on innovative research conducted at Yale University by Dr. Craig Crews, Founder and Chief Scientific Advisor, the company is translating natural protein degradation approaches into novel drugs for the treatment of cancer and other diseases. The proprietary PROTAC-based drug paradigm induces protein degradation, rather than protein inhibition, using the ubiquitin proteasome system and offers the advantage of potentially targeting undruggable as well as druggable elements of the proteome. This greatly expands the ability to create drugs for many new, previously unapproachable targets. For more information, visit www.arvinas.com.

keywords:Biotechnology,Healthcare,Marketing,Pharmaceuticals

85

Number of Employees

$1.3M

Revenue (est)

17

Current Jobs

49%

Employee Growth %

$235.9M

Total Funding

N/A

Valuation

N/A

Accelerator

B2B

Type

Similar Companies

NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
Metrum Research...
$5.1M4021%
Biological Indu...
$10.7M7610%
Biohaven Pharma...
$14.8M5913%$248.3M
IsoPlexis
$6.7M8188%$48.3M
Arvinas
$1.3M8549%$235.9M
Sema4
N/A34028%

Arvinas News

09/03/2019 - Arvinas Announces the Initiation of Patient Dosing in a First-in ...

NEW HAVEN, Conn., Aug. 27, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of ...

09/08/2019 - Arvinas To Present at the Wedbush PacGrow Healthcare ...

NEW HAVEN, Conn. , Aug. 07, 2019 (GLOBE NEWSWIRE) — Arvinas Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of ...

09/03/2019 - Arvinas Inc (NASDAQ:ARVN) Sees Significant Drop in Short Interest

Arvinas Inc (NASDAQ:ARVN) was the target of a significant decline in short interest in the month of July. As of July 31st, there was short interest ...

Arvinas Funding

DateAmountRoundLead InvestorsReference
2013-09-27$15.0MAArticle
2015-10-22$41.6MBRA Capital ManagementArticle
2018-04-05$55.0MCNextech InvestArticle

Arvinas Executive Hires

DateNameTitleReference
2014-02-12Jim WinklerChief Scientific OfficerArticle
2015-01-13Manuel LitchmanPresident/CEOArticle
2015-09-24Robert KleinfieldChief Development OfficerArticle
2016-03-03Angela ShenChief Medical OfficerArticle
2017-01-06John HoustonPresident of Research and Development and Chief Scientific OfficerArticle
2017-09-21John Houstonpresident and chief executive officerArticle